Alexander L Bullen1, Ronit Katz2, Vasantha Jotwani3, Pranav S Garimella4, Alexandra K Lee5, Michelle M Estrella3, Michael G Shlipak6, Joachim H Ix7. 1. Nephrology Section, Veterans Affairs San Diego Healthcare System, La Jolla, CA. 2. Department of Obstetrics & Gynecology, University of Washington, Seattle, WA. 3. Kidney Health Research Collaborative, Department of Medicine, University of California-San Francisco, San Francisco, CA; Department of Medicine, San Francisco VA Medical Center, San Francisco, CA. 4. Division of Nephrology and Hypertension, Department of Medicine, University of California-San Diego, San Diego, CA. 5. Kidney Health Research Collaborative, Department of Medicine, University of California-San Francisco, San Francisco, CA. 6. Kidney Health Research Collaborative, Department of Medicine, University of California-San Francisco, San Francisco, CA; Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA; Department of Medicine, San Francisco VA Medical Center, San Francisco, CA. 7. Nephrology Section, Veterans Affairs San Diego Healthcare System, La Jolla, CA; Division of Nephrology and Hypertension, Department of Medicine, University of California-San Diego, San Diego, CA; Division of Preventive Medicine, Department of Family Medicine and Public Health, University of California-San Diego, San Diego, CA. Electronic address: joix@ucsd.edu.
Abstract
RATIONALE & OBJECTIVE: The Systolic Blood Pressure Intervention Trial (SPRINT) compared the effect of intensive versus standard systolic blood pressure targets on cardiovascular morbidity and mortality. In this ancillary study, we evaluated the use of exploratory factor analysis (EFA) to combine biomarkers of kidney tubule health in urine and plasma and then study their role in longitudinal estimated glomerular filtration rate (eGFR) change and risk of acute kidney injury (AKI). STUDY DESIGN: Observational cohort nested in a clinical trial. SETTING & PARTICIPANTS: 2,351 SPRINT participants with eGFR < 60 mL/min/1.73 m2 at baseline. EXPOSURE: Levels of neutrophil gelatinase-associated lipocalin (NGAL), interleukin 18 (IL-18), chitinase-3-like protein (YKL-40), kidney injury molecule 1 (KIM-1), monocyte chemoattractant protein 1 (MCP-1), α1-microglobulin (A1M) and β2-microglobulin (B2M), uromodulin (UMOD), fibroblast growth factor 23 (FGF-23), and intact parathyroid hormone (PTH). OUTCOME: Longitudinal changes in eGFR and risk of AKI. ANALYTICAL APPROACH: We performed EFA to capture different tubule pathophysiologic processes. We used linear mixed effects models to evaluate the association of each factor with longitudinal changes in eGFR. We evaluated the association of the tubular factors scores with AKI using Cox proportional hazards regression. RESULTS: From 10 biomarkers, EFA generated 4 factors reflecting tubule injury/repair (NGAL, IL-18, and YKL-40), tubule injury/fibrosis (KIM-1 and MCP-1), tubule reabsorption (A1M and B2M), and tubule reserve/mineral metabolism (UMOD, FGF-23, and PTH). Each 1-SD higher tubule reserve/mineral metabolism factor score was associated with a 0.58% (95% CI, 0.39%-0.67%) faster eGFR decline independent of baseline eGFR and albuminuria. Both the tubule injury/repair and tubule injury/fibrosis factors were independently associated with future risk of AKI (per 1 SD higher, HRs of 1.18 [95% CI, 1.10-1.37] and 1.23 [95% CI, 1.02-1.48], respectively). LIMITATIONS: The factors require validation in other settings. CONCLUSIONS: EFA allows parsimonious subgrouping of biomarkers into factors that are differentially associated with progressive eGFR decline and AKI. These subgroups may provide insights into the pathological processes driving adverse kidney outcomes. Published by Elsevier Inc.
RATIONALE & OBJECTIVE: The Systolic Blood Pressure Intervention Trial (SPRINT) compared the effect of intensive versus standard systolic blood pressure targets on cardiovascular morbidity and mortality. In this ancillary study, we evaluated the use of exploratory factor analysis (EFA) to combine biomarkers of kidney tubule health in urine and plasma and then study their role in longitudinal estimated glomerular filtration rate (eGFR) change and risk of acute kidney injury (AKI). STUDY DESIGN: Observational cohort nested in a clinical trial. SETTING & PARTICIPANTS: 2,351 SPRINT participants with eGFR < 60 mL/min/1.73 m2 at baseline. EXPOSURE: Levels of neutrophil gelatinase-associated lipocalin (NGAL), interleukin 18 (IL-18), chitinase-3-like protein (YKL-40), kidney injury molecule 1 (KIM-1), monocyte chemoattractant protein 1 (MCP-1), α1-microglobulin (A1M) and β2-microglobulin (B2M), uromodulin (UMOD), fibroblast growth factor 23 (FGF-23), and intact parathyroid hormone (PTH). OUTCOME: Longitudinal changes in eGFR and risk of AKI. ANALYTICAL APPROACH: We performed EFA to capture different tubule pathophysiologic processes. We used linear mixed effects models to evaluate the association of each factor with longitudinal changes in eGFR. We evaluated the association of the tubular factors scores with AKI using Cox proportional hazards regression. RESULTS: From 10 biomarkers, EFA generated 4 factors reflecting tubule injury/repair (NGAL, IL-18, and YKL-40), tubule injury/fibrosis (KIM-1 and MCP-1), tubule reabsorption (A1M and B2M), and tubule reserve/mineral metabolism (UMOD, FGF-23, and PTH). Each 1-SD higher tubule reserve/mineral metabolism factor score was associated with a 0.58% (95% CI, 0.39%-0.67%) faster eGFR decline independent of baseline eGFR and albuminuria. Both the tubule injury/repair and tubule injury/fibrosis factors were independently associated with future risk of AKI (per 1 SD higher, HRs of 1.18 [95% CI, 1.10-1.37] and 1.23 [95% CI, 1.02-1.48], respectively). LIMITATIONS: The factors require validation in other settings. CONCLUSIONS: EFA allows parsimonious subgrouping of biomarkers into factors that are differentially associated with progressive eGFR decline and AKI. These subgroups may provide insights into the pathological processes driving adverse kidney outcomes. Published by Elsevier Inc.
Authors: Walter T Ambrosius; Kaycee M Sink; Capri G Foy; Dan R Berlowitz; Alfred K Cheung; William C Cushman; Lawrence J Fine; David C Goff; Karen C Johnson; Anthony A Killeen; Cora E Lewis; Suzanne Oparil; David M Reboussin; Michael V Rocco; Joni K Snyder; Jeff D Williamson; Jackson T Wright; Paul K Whelton Journal: Clin Trials Date: 2014-06-05 Impact factor: 2.486
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Daniel F Gudbjartsson; Hilma Holm; Olafur S Indridason; Gudmar Thorleifsson; Vidar Edvardsson; Patrick Sulem; Femmie de Vegt; Frank C H d'Ancona; Martin den Heijer; Jack F M Wetzels; Leifur Franzson; Thorunn Rafnar; Kristleifur Kristjansson; Unnur S Bjornsdottir; Gudmundur I Eyjolfsson; Lambertus A Kiemeney; Augustine Kong; Runolfur Palsson; Unnur Thorsteinsdottir; Kari Stefansson Journal: PLoS Genet Date: 2010-07-29 Impact factor: 5.917
Authors: Danilo Fliser; Barbara Kollerits; Ulrich Neyer; Donna P Ankerst; Karl Lhotta; Arno Lingenhel; Eberhard Ritz; Florian Kronenberg; Erich Kuen; Paul König; Günter Kraatz; Johannes F E Mann; Gerhard A Müller; Hans Köhler; Peter Riegler Journal: J Am Soc Nephrol Date: 2007-07-26 Impact factor: 10.121
Authors: Ladan Golestaneh; Paula J Alvarez; Nancy L Reaven; Susan E Funk; Karen J McGaughey; Alain Romero; Melanie S Brenner; Macaulay Onuigbo Journal: Am J Manag Care Date: 2017-06 Impact factor: 2.229
Authors: Vasantha Jotwani; Pranav S Garimella; Ronit Katz; Rakesh Malhotra; Jeffrey Bates; Alfred K Cheung; Michel Chonchol; Paul E Drawz; Barry I Freedman; William E Haley; Anthony A Killeen; Henry Punzi; Mark J Sarnak; Mark S Segal; Michael G Shlipak; Joachim H Ix Journal: Am J Nephrol Date: 2020-09-09 Impact factor: 3.754
Authors: Pranav S Garimella; Alexandra K Lee; Walter T Ambrosius; Udayan Bhatt; Alfred K Cheung; Michel Chonchol; Timothy Craven; Amret T Hawfield; Vasantha Jotwani; Anthony Killeen; Henry Punzi; Mark J Sarnak; Barry M Wall; Joachim H Ix; Michael G Shlipak Journal: Eur Heart J Date: 2019-11-01 Impact factor: 35.855
Authors: Andrea Galassi; Eliana Maria Fasulo; Paola Ciceri; Roberta Casazza; Fabrizio Bonelli; Claudia Zierold; Mariella Calleri; Frank A Blocki; Maria Assunta Palmieri; Claudio Mastronardo; Mario G Cozzolino Journal: Front Med (Lausanne) Date: 2022-03-02